Clinical Trials

CannTrust is getting ready to launch a clinical trial to assess the effectiveness of its cannabidiol (CBD) oil capsules on slowing the progression of amyotrophic lateral sclerosis (ALS) and other motor neuron diseases (MNDs). This new study is the result of a collaboration between Canada-based CannTrust and Gold Coast University Hospital, one of the leading tertiary […]

<!– Market News –> July 15, 2018 – By Joseph Taylor Oz Management Lp decreased Insys Therapeutics Inc New (Put) (INSY) stake by 66.22% reported in 2018Q1 SEC filing. Oz Management Lp sold 58,800 shares as Insys Therapeutics Inc New (Put) (INSY)’s stock declined 15.10%. The Oz Management Lp holds 30,000 shares with $181,000 value, […]

The study is designed to evaluate the efficacy of CannTrust’s Cannabidiol Oil Capsules in slowing Amyotrophic Lateral Sclerosis (ALS) progression VAUGHAN, ON, July 11, 2018 /PRNewswire/ – CannTrust Holdings Inc. (“CannTrust” or the “Company”, TSX: TRST), one of Canada’s leading licensed producers of medical cannabis, announced today that it has partnered with Australia’s Gold Coast […]

Zynerba Pharmaceuticals has launched a pivotal Phase 3 clinical trial, called CONNECT-FX, that will assess the safety and effectiveness of its cannabis-based ZYN002 as a potential therapy to treat behavioral symptoms in patients with fragile X syndrome. Top-line results from the trial are expected in the second half of 2019. ZYN002 is administered as a gel through […]

The six-month study will be led by Gold Coast Neurologist, Dr. Arman Sabet, MD. Gold Coast is one of Australia’s leading tertiary referral institutions for ALS management and Dr. Sabet has been involved in many international clinical trials specializing in neuromuscular disorders and stroke. Dr. Sabet’s research will also analyze the effects of CannTrust CBD […]

CannTrust Holdings announced its involvement in a six-month clinical trial to determine the effectiveness of CBD oil capsules treating ALS or Motor Neuron Disease. CannTrust Holdings (TSX:TRST) announced its involvement in a six-month clinical trial to determine the effectiveness of cannabidiol (CBD) oil capsules treating Amyotrophic Lateral Sclerosis (ALS) or Motor Neuron Disease (MND). As quoted […]

The study is designed to evaluate the efficacy of CannTrust’s Cannabidiol Oil Capsules in slowing Amyotrophic Lateral Sclerosis (ALS) progression VAUGHAN, ON, July 11, 2018 /CNW/ – CannTrust Holdings Inc. (“CannTrust” or the “Company”, TSX: TRST), one of Canada’s leading licensed producers of medical cannabis, announced today that it has partnered with Australia’s Gold Coast […]

DEVON, PA — Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the initiation of a multi-national, randomized, double-blind placebo-controlled Clinical study of Cannabidiol (CBD) in Children and Adolescents with Fragile X (CONNECT-FX). The CONNECT-FX trial will evaluate the efficacy and safety of ZYN002 (CBD […]

Zynerba Pharmaceuticals has commenced the CONNECT-FX trial, a pivotal clinical trial designed to examine the efficacy and safety of ZYN002 to treat patients with Fragile X syndrome (FXS). The multi-national, randomised, double-blind placebo-controlled clinical study of Cannabidiol (CBD) in Children and Adolescents with Fragile X (CONNECT-FX) aims to enrol around 200 FXS patients aged between […]

Study will Evaluate the Efficacy and Safety of Transdermally-Delivered Cannabidiol (CBD) in Children and Adolescents with Fragile X Syndrome Top Line Results Expected in Second Half of 2019 Zynerba to host conference call and webcast today at 8:30 am DEVON, Pa., July 09, 2018 (GLOBE NEWSWIRE) —  Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative […]

A drug made from a derivative of marijuana has been approved for patients with certain forms of epilepsy. Blaine Harrington III/Getty Images hide caption toggle caption … read more at: https://www.npr.org/sections/health-shots/2018/06/25/623236189/fda-green-lights-marijuana-based-pharmaceutical-drug